Dynavax Technologies Co. (NASDAQ:DVAX) Insider Sells $60,000.00 in Stock

Dynavax Technologies Co. (NASDAQ:DVAX – Get Rating) insider Justin Burgess sold 6,000 shares of the firm’s stock in a transaction dated Tuesday, May 17th. The shares were sold at an average price of $10.00, for a total value of $60,000.00. Following the transaction, the insider now owns 3,854 shares in the company, valued at $38,540. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link.

Justin Burgess also recently made the following trade(s):

• On Thursday, March 3rd, Justin Burgess sold 21,490 shares of Dynavax Technologies stock. The shares were sold at an average price of $10.58, for a total value of $227,364.20.

Dynavax Technologies stock opened at $9.62 on Thursday. The company has a debt-to-equity ratio of 0.99, a quick ratio of 1.64 and a current ratio of 1.75. The business’s 50-day simple moving average is $10.15 and its 200-day simple moving average is $12.67. The firm has a market capitalization of $1.22 billion, a PE ratio of 17.49 and a beta of 1.44. Dynavax Technologies Co. has a 52 week low of $7.26 and a 52 week high of $21.39.

Dynavax Technologies (NASDAQ:DVAX – Get Rating) last released its earnings results on Thursday, May 5th. The biopharmaceutical company reported $0.22 earnings per share for the quarter, missing analysts’ consensus estimates of $0.24 by ($0.02). Dynavax Technologies had a return on equity of 115.98% and a net margin of 23.12%. The firm had revenue of $113.99 million for the quarter, compared to analyst estimates of $117.76 million. During the same period last year, the business earned $0.01 earnings per share. Research analysts forecast that Dynavax Technologies Co. will post 1.14 earnings per share for the current year.

Several research firms have weighed in on DVAX. StockNews.com lowered Dynavax Technologies from a “buy” rating to a “hold” rating in a report on Thursday, May 12th. TheStreet upgraded Dynavax Technologies from a “d+” rating to a “c” rating in a report on Wednesday, March 30th. Finally, Zacks Investment Research lowered Dynavax Technologies from a “buy” rating to a “hold” rating in a research note on Tuesday, March 1st. Three equities research analysts have rated the stock with a hold rating and two have given a buy rating to the company’s stock. According to data from MarketBeat.com, Dynavax Technologies currently has an average rating of “Hold” and an average target price of $21.00.

A number of hedge funds have recently added to or reduced their stakes in DVAX. Marshall Wace LLP boosted its holdings in Dynavax Technologies by 225.0% during the first quarter. Marshall Wace LLP now owns 16,449 shares of the biopharmaceutical company’s stock valued at $120,000 after purchasing an additional 11,387 shares in the last quarter. Invesco Ltd. boosted its holdings in Dynavax Technologies by 48.6% during the second quarter. Invesco Ltd. now owns 39,236 shares of the biopharmaceutical company’s stock valued at $386,000 after purchasing an additional 12,838 shares in the last quarter. Wells Fargo & Company MN boosted its holdings in Dynavax Technologies by 172.5% during the second quarter. Wells Fargo & Company MN now owns 168,815 shares of the biopharmaceutical company’s stock valued at $1,663,000 after purchasing an additional 106,872 shares in the last quarter. Morgan Stanley boosted its holdings in Dynavax Technologies by 176.1% during the second quarter. Morgan Stanley now owns 1,789,695 shares of the biopharmaceutical company’s stock valued at $17,629,000 after purchasing an additional 1,141,462 shares in the last quarter. Finally, Advisor Group Holdings Inc. boosted its holdings in Dynavax Technologies by 51.3% during the third quarter. Advisor Group Holdings Inc. now owns 50,044 shares of the biopharmaceutical company’s stock valued at $958,000 after purchasing an additional 16,964 shares in the last quarter. 76.80% of the stock is currently owned by institutional investors and hedge funds.

Dynavax Technologies Company Profile (Get Rating)

Dynavax Technologies Corporation, a biopharmaceutical company, focuses on developing and commercializing novel vaccines in the United States. The company markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe.

Further Reading